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Abstract  
The cell cycle is tightly regulated by cyclins and their catalytic moieties, the cyclin-
dependent kinases (CDKs). Cyclin D1, in association with CDK4/6, acts as a mitogenic sensor 
and integrates extracellular mitogenic signals and cell cycle progression. When deregulated 
(overexpressed, accumulated, inappropriately located), cyclin D1 becomes an oncogene and 
is recognized as a driver of solid tumors and hemopathies. Recent studies on the oncogenic 
roles of cyclin D1 reported non-canonical functions dependent on the partners of cyclin D1 
and its location within tumor cells or tissues. Support for these new functions was provided 
by various mouse models of oncogenesis. Finally, proteomic and transcriptomic data 
identified complex cyclin D1 networks. This review focuses on these aspects of cyclin D1 
pathophysiology, which may be crucial for targeted therapy. 
 
Introduction 
The cell cycle and cell proliferation/division are driven by cyclins and their catalytic 
partners, the cyclin-dependent kinases (CDKs) (Figure 1A). Diverse heterodimeric complexes 
form, with D-type cyclins (D1, D2 and D3) associating with CDK4 or CDK6 (CDK4/6, two 
serine/threonine kinases functionally redundant in most tissues, [1]), to control the 
progression through the G1 phase, the G1-to-S phase transition, thereby initiating DNA 
replication [2]. The expression, activation, subcellular distribution, stabilization and 
degradation of D-type cyclins are tightly controlled in normal cells in response to on/off 
mitogenic signals. In turn, the overexpression, accumulation and mislocalization of D-type 
cyclins drive human tumors and may confer resistance to chemotherapy. Cyclin D1 is more 
frequently deregulated than cyclins D2 and D3 in solid cancers and malignant hemopathies 
[3]. Indeed, the CCND1 gene encoding cyclin D1 is the second most  frequently amplified locus 
 3 
in solid cancers [4]. In hematological malignancies, cyclin D1 is overexpressed due to 
t(11;14)(q13;q32) translocation, amplification of the CCND1 gene, deletion or point mutations 
within the CCND1 3’-UTR or the first exon [5, 6]. Cyclin D1 activity is strongly linked to its levels. 
Tumor cells with high cyclin D1 levels display uncontrolled proliferation in response to a cell 
cycle dysfunction at the restriction point in the G1 phase (Figure 1A). In addition to this role 
in regulating the cell cycle, in which it acts in association with CDK4/6 or other partners such 
as transcription factors, chromatin-modifying enzymes or cytosolic proteins, cyclin D1 also 
regulates a number of key processes involved in cancer initiation and maintenance. These 
processes include DNA damage response [7, 8], chromosome duplication and stability [9, 10], 
senescence [11, 12], autophagy [11, 13], mitochondrial respiration [14, 15], migration [16-18], 
metabolism [19-21], and immune surveillance [22, 23]. Cyclin D1 shuttles between the nucleus 
and the cytoplasm and has also been found associated with the outer membrane of the 
mitochondria [15] or close to the cytoplasmic membranes, at ruffles in migrating cells [24]. 
Some of the oncogenic functions of cyclin D1 are performed by the nuclear form, whereas 
others are performed by the cytosolic or membrane-bound forms. Recent reviews on the 
structure, function, and regulation of cyclin D1 have been published  [5, 25-27]. In this review, 
we focus on the most meaningful findings of recent years. We focus on the pathophysiological 
functions of cyclin D1 in relation to its subcellular distribution, because these relatively recent 
observations may have a profound impact on clinical practice. We highlight the importance of 
addressing the diversity of cyclin D1-associated functions with a view to developing targeted 
therapies, and the questions that remain unanswered. 
 
Cyclin D1 shuttles between the nucleus and the cytoplasm in normal cells 
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 Cyclin D1 levels oscillate and its subcellular distribution changes over the course of the 
normal cell cycle. Cyclin D1 levels are highly regulated at the transcriptional, post-
transcriptional and translational steps [26]. The synthesis of CCND1 mRNA and protein begins 
when mitogenic stimulation induces quiescent cells to enter G1. Cyclin D1 expression requires 
the activation of RAS-mediated signaling cascades, which is accompanied by 
phosphoinositide-3-kinase (PI3K)/AKT-dependent CCND1 translation and a decrease in cyclin 
D1 degradation. The active cyclin D1/CDK4/6 complexes move to the nucleus, and cyclin D1 
levels increase from early to late G1 phase, subsequently decreasing during S phase, when 
cyclin D1 is exported into the cytoplasm for degradation by the ubiquitin-proteasome system 
(UPS). This requires the phosphorylation of the threonine 286 (Figure 1B), which is catalyzed 
by, at least, three kinases: glycogen synthase-3β (GSK3β), p38 MAP kinase (MAPK) and 
extracellular signal-regulated kinases (ERK1/2) [28, 29]. In the cytoplasm, the ubiquitylation 
of phosphorylated cyclin D1 is dependent on a SCF complex consisting of the SKP1 adaptor 
protein,  the CUL1 scaffold protein and a F-box protein. At least four E3 ubiquitin ligases of the 
F-box family ubiquitylate cyclin D1. Three of them (SKP2, FBXW8, FBXO4) are involved in the 
normal cell cycle whereas as FBXO31 acts in response to genotoxic stresses [30-33]. Mutations 
or alterations of cyclin D1-specific E3 ubiquitin ligases contribute to cyclin D1 accumulation in 
cancers [33, 34]. In turn, the promotion of cyclin D1 degradation suppresses cancer cell 
growth. This can be achieved by the knockdown of USP2 coding a cyclin D1-specific 
deubiquitylase or by the use of inhibitors [35, 36].  
 Cyclin D1 has a nuclear export signal and is a cargo of exportin 1 (XPO1). However, it has 
no nuclear localization signal and cannot enter the nucleus on its own. Instead, its nuclear 
entry is favored both by the CIP/KIP (CDK-interacting protein, kinase inhibitory protein) family 
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members and CDK4, and cyclin D1/CDK4/p21CIP1/p27KIP1 complexes are imported into the 
nucleus upon activation (Figure 1C).  
 
Cyclin D1 accumulates in the nucleus and/or in the cytoplasm in tumor cells or specialized 
tumor regions  
Cyclin D1 is overexpressed in many human solid cancers, including breast cancers, 
particularly those with the estrogen receptor (ER)-positive subtype [37], head and neck 
squamous cell carcinoma [38], pancreatic cancer [39], melanoma [40], endometrial cancer 
[41], colorectal carcinoma [42], and non-small cell lung carcinoma [43] (Figure 2A). In mantle 
cell lymphoma, a mature B-cell lymphoma, the t(11;14)(q13;q32) translocation leads to the 
overexpression of cyclin D1 in almost 100% of patients [44]. This translocation is found in 15% 
of multiple myeloma patients, but cyclin D1 is overexpressed in the absence of a detectable 
genetic alteration in 50% of multiple myelomas [45].  
Cyclin D1 overexpression may occur due to CCND1 amplification or chromosomal 
rearrangements, or as a result of impaired degradation of the protein. Mutations and 
deletions affecting the threonine 286 (Thr286) residue, the site of the glycogen synthase-3β 
(GSK3β) phosphorylation required for nuclear export by XPO1 and subsequent degradation by 
the UPS, have been reported in endometrial cancers and esophageal carcinomas [46, 47]. As 
a result, cyclin D1 is constitutively nuclear in these cells. In MCL cells, genomic deletions 
and/or points mutations in the 3’-UTR of the CCND1 mRNA result in the generation of a 
shorter, more stable transcript [48, 49]. Recent genomic studies on MCL identified recurrent 
mutations in the 5’-coding region of CCND1 that increased cyclin D1 stability due to a defect 
in UPS-mediated degradation [6]. In all cases, the mutated proteins preferentially localize to 
the nucleus. In lung and colorectal cancers, the deubiquitylase USP22 (ubiquitin-specific 
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peptidase 22), a subunit of the Spt-Ada-Gcn5-acetyltransferase (SAGA) transcriptional 
coactivator, and cyclin D1 levels are correlated. Moreover, by directly deubiquitylating cyclin 
D1, USP22 protects it from UPS-mediated degradation allowing its accumulation through a 
novel mechanism [50].  
 CCND1 has an A/G polymorphism at nucleotide 870, at the splice donor site of the exon 
4-intron 4 boundary. This polymorphism leads to alternative splicing, generating a cyclin D1 
variant called cyclin D1b [50] (Figure 1B). The mature cyclin D1b transcript includes exon 4 and 
intron 4. The corresponding isoform b of the protein lacks the Thr286 required for cyclin D1 
degradation. Cyclin D1b is constitutively nuclear [52], and is present in MCL, esophageal, 
breast, lung and prostate cancers [53]. Cyclin D1b has a lower capacity to phosphorylate the 
retinoblastoma protein RB1 [52, 54], the central regulator of the cell cycle, but a greater 
oncogenic capacity than the canonical cyclin D1 (cyclin D1a) [51, 55]. Cyclin D1b (and not cyclin 
D1a) is capable of transforming NIH-3T3 cells (foci formation) in vitro [52]. Cyclin D1b-
producing fibroblasts lost contact inhibition, form colonies in soft agar and engraft in 
immunodeficient mice [54]. These observations highlight the contribution of nuclear functions 
other than cell cycle regulation to oncogenesis. Moreover, the expression of cyclin D1b, unlike 
that of cyclin D1a, is unambiguously associated with tumor progression and treatment failure 
in prostate and breast cancer [53, 56-58]. Using an engineered mouse model in which cyclin 
D1a was converted into cyclin D1b under the control of the endogenous CCND1 promoter, 
Augello and coworkers confirmed that these two isoforms, despite being regulated in a similar 
fashion, had different functions, with cyclin D1b having a much greater oncogenic potential. 
Indeed, cyclin D1b fosters transformation of primary fibroblasts and cooperate with the RAS 
oncogene to drive transformation in vivo [56]. Moreover, Gladden and coworkers had 
previously described a mouse model in which a constitutively nuclear form of cyclin D1 
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(T286A, Figure 1B) was under the control of the heavy chain immunoglobulin enhancer Eμ 
[59]. All transgenic mice developed mature B-cell lymphomas, providing further evidence for 
the oncogenicity of the nuclear form of cyclin D1.  
The nuclear accumulation of cyclin D1 is indicative of a high mitotic index in cancer cells, 
and is considered to be a prognostic marker. On the other hand, high cyclin D1a levels are 
inversely correlated with with levels of Ki67, a marker of cell proliferation, and are unrelated 
to clinical outcome [58]. By contrast, cyclin D1b is also upregulated in breast cancers, including 
ER-negative tumors, independently of cyclin D1a, and is associated with a poor outcome, with 
recurrence and distant metastasis [58]. In other types of cancer, such as prostate cancer cells, 
cyclin D1 accumulates in either the cytoplasm or the nucleus. Tumors with cytoplasmic cyclin 
D1 accumulation have the lowest Ki67 index, whereas those with nuclear cyclin D1 
accumulation are of higher grade and have high Ki67 levels [60]. Interestingly, in prostate 
cancer metastases, a high cytoplasmic cyclin D1 content is predictive of poor outcome [61]. 
Fusté and coworkers reported that cyclin D1 was mainly cytoplasmic, being found even at the 
membranes in peripheral and invasive tissues of breast, prostate, colon, and endometrial 
cancers, suggesting that it might be useful as a marker of invasiveness [62]. Cyclin D1 has been 
detected in both the nuclear and cytoplasmic compartments of MCL tumor cells. However, it 
was mostly cytoplasmic in the more aggressive, blastoid form of the disease [63]. In 
glioblastoma, cyclin D1 is mostly cytoplasmic in evading cells but retained within the nucleus 
in the tumor mass [64]. These observations confirm that cyclin D1 has unrelated nuclear and 
cytoplasmic functions.  
 
Nuclear cyclin D1 has oncogenic roles 
 Nuclear cyclin D1 controls cell proliferation 
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 In normal cells, cyclin D1 is produced in response to extracellular mitogenic signals and 
the subsequent activation of RAS-dependent signaling cascades, cyclin D1/CDK4/6 complexes 
assemble, are stabilized and activated (Figure 1C) [65]. CDK inhibitors of the CIP1/KIP family 
facilitate cyclin D1/CDK4/6 assembly and nuclear import without inhibiting the kinase activity 
[64]. Once within the nucleus, D1/CDK4/6 complexes control the G1-to-S phase transition and 
promote cell cycle progression. Cyclin D1/CDK4/6 complexes phosphorylate RB1 and related 
pocket proteins (RBL1/2, p107 and p130), thereby dissociating E2F transcription factors, which 
activate genes controlling the G1-to-S phase transition. When S phase is completed, cyclin D1 
is exported to the cytoplasm and degraded. The deregulation of these steps leads to the 
accumulation of cyclin D1. Cell proliferation becomes independent of extracellular signals, and 
the cell cycle checkpoints responsible for ensuring genome integrity are bypassed [66].  
Cyclin D1/CDK4/6 complexes also phosphorylate several transcription factors, thereby 
activating or repressing the expression of genes required for cell cycle progression. SMAD3, 
which inhibits the the anti-proliferative effect of the transforming growth factor (TGF)-β 
signaling pathway, is a target of cyclin D1/CDK4 complexes [66]. Several cyclin D1/CDK4 
phosphorylation sites have been mapped on SMAD3. Mutations of these sites increase SMAD3 
transcriptional activity and antiproliferative functions [67]. Cyclin D1/CDK4 phosphorylates 
and activates the transcription factor forkhead box M1 (FOXM1) thereby maintaining the 
expression of G1/S-phase genes, promoting the cell cycle and preventing senescence [68].  
 
Nuclear cyclin D1 controls transcription 
The best-known function of nuclear cyclin D1 independent of CDK4/6 activity is its 
ability to act as a cofactor for transcription and to modulate pathways critical for both 
development, differentiation and tumorigenesis [69]. The DNA binding capacity of cyclin D1, 
 9 
leading to the repression of the CDKN1A gene (encoding p21CIP1) transcription was reported 
in 2005 [70]. Genomic and proteomic screens have since revealed that the cyclin D1 
interactome comprises more than 30 transcriptional regulators, including nuclear receptors 
[71]. Mechanistically, the control of transcription involves both transcription factors and 
chromatin-modifying enzymes. 
Among nuclear receptors, cyclin D1 binds and directly controls the transcription of 
estrogen receptor (ER)α, peroxisome proliferator-activated receptors (PPARs), and androgen 
receptor (AR) in breast, prostate and liver cancer cells respectively [45]. Cyclin D1 upregulates 
ERα-mediated transcription. It binds the hormone-binding domain of ERα, thereby increasing 
ERα-mediated activity even in the absence of the canonical ligand. Cyclin D1 also interacts 
with steroid receptor coactivators (SRC1 and SRC3), which recruit additional transcriptional 
cofactors, such as PCAF (p300/CREB binding-associated protein), a histone acetyltransferase, 
and modify chromatin structure. This increases the transcriptional activity of the ER [72]. The 
cyclin D1b isoform is present in breast cancer cells but does not bind ERα [73]. By contrast, in 
prostate cancer cells, cyclin D1a binds AR and represses ligand-dependent activity through 
two discrete mechanisms: direct binding to prevent the formation of an active conformation 
and binding to histone deacetylase (HDAC), which mediates transcriptional repression [74]. 
Cyclin D1b retains the ability to bind AR and stimulates androgen-dependent proliferation 
[75]. In prostate cancer cells, cyclin D1b promotes the activation of AR-dependent genes 
associated to a metastatic phenotype, including SNAI2, encoding Slug, in particular, 
independently of an epithelial-mesenchymal transition (EMT) signature [37]. Cyclin D1b and 
Slug levels are strongly correlated in clinical samples from patients with advanced disease. 
Cyclin D1 inhibits the transcriptional activity of PPARγ. It also enhances the recruitment of 
HDAC and histone methyltransferase (such as SuV39H) to the PPAR-response element [76] 
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and inhibits the transcriptional activity of PPARα through an unknown mechanism, thereby 
acting on fatty acid metabolism and energy homeostasis [20]. The oncogenic function of cyclin 
D1-mediated PPARs activation remains to be established. 
A direct interaction between cyclin D1 and transcription factors, such as STAT3 (signal 
transducer and activator of transcription 3) and DMP1 (dentin matrix acidic phosphoprotein 
1) is involved in cell transformation in breast cancers [77]. In cells with cyclin D1 expression, 
CDKN1A (encoding p21CIP1) is downregulated. Indeed, cyclin D1 is recruited to the p21CIP1 
promoter by STAT3 and represses its activity [70]. Cyclin D1 bound to DMP1 activates the ARF 
(encoding p14) and INK4A (encoding p16) promoters of the CDKN2A locus [78]. In normal cells, 
this activation induces apoptosis or cell cycle delay and protects cells from transformation. In 
breast cancer cells, DMP1 is frequently lost, and oncogenic signals from ARF and INK4A 
promoters are no longer quenched. This observation has been reproduced in mouse models 
[78]. Cyclin D1 also interacts with other transcription factors from the MYB family. However, 
the impact of this regulation on cell transformation remains unclear [77]. 
It has recently been shown that cyclin D1 binds a large number of active promoters in 
MCL cells, massively downregulating global transcription [79]. It has been suggested that this 
downregulation of the transcription program has an oncogenic impact on the levels of tumor 
suppressor proteins, including the products of cell-cycle checkpoint genes. Moreover, the 
overexpression of cyclin D1 leads to the accumulation of paused polymerase II (Pol II), which 
may lead to genomic instability by increasing the probability of potential conflicts between 
DNA replication and transcription machineries. Importantly, cyclin D1 overexpression 
sensitizes cells to transcription inhibitors, generating a synthetic lethality interaction [79]. This 
global dysregulation of transcription has not been reported for solid cancers, but the 
interactomes of cyclin D1 are similar in solid tumors and hemopathies [8].  
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 The DNA-bound form of cyclin D1 regulates gene transcription through histone 
regulatory enzymes, such as histone deacetylase (HDAC1/3) and histone acetyltransferase 
(HAT), and chromatin remodeling enzymes such as SUV39H (suppressor of variegation 3-9 
homolog) and HP1α (or CBX5, chromobox 5). Further evidence for the control of epigenetic 
marks by cyclin D1 was recently provided by the finding that cyclin D1 controls global protein 
methylation by binding directly to G9a lysine methyltransferase [80]. Using ChIP-Seq 
(chromatin-immunoprecipitation and DNA sequencing) technology to map the global genomic 
footprint of cyclin D1, Pestell’s group identified 3200 DNA regions associated with cyclin D1 
throughout the genome. They investigated the transcription sites displaying enrichment in 
these regions and identified CTCF, SP1, ESR1 (encoding ERα), CREB1 and HIF1A genes as 
master hits [10]. Interestingly, CTCF (or CCCTC-binding factor) is a zinc finger transcription 
factor serving as an essential anchor site for ERα-mediated proliferation in breast cancer cells 
[81]. The relevance of the other transcription factors in cyclin D1-mediated tumorigenesis has 
not been investigated. However, Casimiro and coworkers showed an enrichment for cyclin D1 
at genes encoding proteins regulating mitosis and chromosomal stability [10].  
  
Nuclear cyclin D1 controls the DNA damage response and genomic stability 
DNA replication, metabolic/redox stresses, chemotherapy and ionizing radiation (IR) lead to 
double-strand DNA breaks (DSBs). Upon DNA damage, DNA-PK (DNA-dependent protein 
kinase), ATM (ataxia telangiectasia mutant) and ATR (ATM and Rad3-related) apical kinases 
and their downstream effectors, including the checkpoint kinases (CHK1/2), activate the DDR 
(DNA damage response) pathway [82]. Depending on the cellular context, the cells then 
initiate cell cycle arrest and DNA repair. They then pursue the cell cycle or undergo senescence 
or apoptosis. The notion that the degradation of cyclin D1 is necessary for cells in G1 to repair 
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DNA and to undergo DNA synthesis dates back to several decades [83]. The expression of the 
nuclear mutant resistant to UPS-mediated degradation results in greater DNA damage [84]. 
Cyclin D1 overexpression, as observed in cancer cells, antagonizes the checkpoint-induced cell 
cycle arrest, disturbs DNA replication and allows damaged DNA to be replicated [7, 84, 85]. 
Cells that have accumulated DNA breaks are prone to genomic instability, and are 
characterized by the loss or gain of whole or pieces of chromosomes, chromosomal 
rearrangements and tumor formation [56, 59, 86, 87]. Casimiro and coworkers showed, in 
several mouse models of breast cancer, that cyclin D1, independently of CDK4/6, regulated a 
transcriptional program governing chromosome instability at the level of local chromatin [10, 
88]. Cyclin D1 may contribute to oncogenesis by regulating a transcriptional program involved 
in chromosome instability.  
Cyclin D1 directly controls the DDR pathway, as a far downstream effector [89]. Indeed, 
the silencing of cyclin D1 impairs the DSB repair mediated by the NHEJ (non-homologous end 
joining) mechanism by inhibiting DNA-PK activation [90]. Moreover, cyclin D1 interacts 
directly with DNA repair proteins, such as activated ATM/DNA-PK and RAD51 [8, 90]. Cyclin 
D1 binds to the DNA repair BRCA1 (breast cancer 1) protein, but the consequences of this 
interaction with regards to DNA repair and cell survival remain unclear [91]. Cyclin D1 binds 
to RAD51, inducing the phosphorylation of H2AX, the assembly of the RAD51-containing repair 
machinery, and the recruitment of these repair factors to chromatin [7]. This property is 
restricted to the isoform a of the protein. Cyclin D1 is also part of the RAD51/BRCA2 (breast 
cancer 2) complexes at DNA damage sites and has been shown to facilitate HR (homologous 
recombination)-mediated DNA repair in a CDK4-independent fashion in several types of 
tumors [8, 92]. Cyclin D1 seems to play a dual role, sustaining the activation of DNA-PK and 
ATM whilst interacting with the DNA repair machinery. However, it remains unknown how 
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this function of cyclin D1 in DNA repair affects the response of cancer cells to DNA damage in 
vivo.  
Steroid hormones, including estrogens and androgens, may induce genotoxic stress, 
leading in turn to DNA damage. In breast cancer cells stimulated with estrogen, ERα and cyclin 
D1 assemble at the cytoplasmic membrane, activate the AKT pathway, and induce the 
formation of γH2AX (the marker of DSBs) foci. Cyclin D1 is recruited to γH2AX foci by RAD51, 
leading to the recruitment of the DNA machinery responsible for HR-mediated DNA repair 
[93]. In prostate cancer cells, cyclin D1 promotes DNA repair via a similar RAD51-mediated 
mechanism [13]. The nuclear CDK4/6-dependent and -independent functions of cyclin D1 are 
represented in Figure 3. 
 
Cytoplasmic and membrane-associated cyclin D1 regulates tumor cells invasion and 
dissemination 
Cell migration and invasion are hallmarks of cancer, leading to tumor cell expansion 
and dissemination through metastasis [94]. Tumors use several strategies to spread within 
tissues, involving mesenchymal, ameboid single-cell migration or collective movements. Most 
of cell processes involved in migration (cell polarization and protrusion, cell contraction, cell 
detachment) require a reorganization of the cytoskeleton [95]. Cyclin D1 has been known to 
play a major role in tumor cell migration, since the seminal work of Pestell’s group on Ccnd1-
/- mouse macrophages [16] and embryonic fibroblasts [17]. Epithelial cells depleted of cyclin 
D1 display enhanced adhesion and reduced migration [17, 18]. Cyclin D1 promotes cell 
motility by inhibiting Rho-activated kinase II (ROCKII) signaling and repressing the  
thrombospondin 1 (TSP1), a metastasis repressor. This process requires cyclin D1/CDK4/6 
activity and the phosphorylation of cytoskeleton proteins involved in cell shape remodeling 
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(Table 1) [96]. Zhong and coworkers identified several cytoskeleton-related proteins 
phosphorylated by cyclin D1/CDK4/6 complexes [24]. Cytoplasmic cyclin D1 regulates cell 
invasion and metastasis through the phosphorylation of paxillin and RAC1 activation, and 
promotes cell ruffling and invasion [97]. Cyclin D1 has been found associated with paxillin at 
the cell membrane in those migrating cells. Paxillin is also the downstream target of 
cytoplasmic cyclin D1/CDK4/6 In glioblastoma [64]. Clinical observations support this major 
role of cytoplasmic cyclin D1 in invasion and metastasis [62, 64].  
In B lymphoma tumor cells, a high cytoplasmic cyclin D1 content is associated with a 
greater invasion capacity. Cytoplasmic cyclin D1 associates with structural proteins of the 
cytoskeleton, affecting cell shape. Cytoplasmic cyclin D1 is present in the blastoid invasive 
variant of MCL, associated with a poor prognosis [63]. Indeed, MCL cells can engraft at various 
locations in the body, according to their cytoplasmic cyclin D1 content and invasive capacity 
[63].  
In addition to transcriptional regulation, cyclin D1 regulates non-coding miRNAs [96] 
and induces the expression of DICER, the central regulator of miRNA maturation at 
transcriptional level [99]. The cyclin D1-mediated proliferation and migration of breast cancer 
cells are DICER-dependent.  
 The nuclear accumulation of cyclin D1 is a marker of proliferation. If cytoplasmic cyclin 
D1 levels are a bona fide marker of invasiveness, then it will be important to determine the  
distribution of cyclin D1 in tumors. Another important finding, albeit not replicated in all 
settings (Table 2), is the CDK4/6-dependence of cyclin D1-mediated migration and invasion. 
The targeting of CDK4 and CDK6 is therefore highly relevant for therapeutic purposes [2, 27].  
 
Cell metabolism is regulated by both nuclear and cytoplasmic cyclin D1  
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Studies of transgenic mice expressing an antisense construct against cyclin D1 (ErbB2-
cyclin D1 antisense) or overexpressing cyclin D1 (MMTV-cyclin D1) in the mammary gland have 
shown that cyclin D1 inhibits oxidative glycolysis, lipogenesis and mitochondrial activity [14]. 
Cyclin D1 decreases hexokinase 2 (HK2) abundance and transcription; HK2 is the first enzyme 
of the glycolysis pathway [14]. Thus, cyclin D1 depletion from normal or cancerous breast cells 
leads to an increase in the levels of the glycolytic enzyme pyruvate kinase (PK) and of the 
lipogenic enzymes acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN). In B 
lymphocytes, HK2 and cyclin D1 compete for binding to VDAC (voltage-dependent anion 
channel) at the outer membrane of the mitochondria [15]. Cyclin D1 bound to VDAC releases 
HK2, which may then participate in and enhance glycolysis (Caillot et al., in preparation). In 
hepatocytes, cyclin D1 represses gluconeogenesis and oxidative phosphorylation by inhibiting 
the PPARγ co-activator, PGC1α. This inhibition is CDK4/6-dependent and is dependent on the 
fasting and refeeding of hepatocytes [100]. It has been suggested that this regulatory pathway 
has an effect on diabetes, rather than cancer. Again in hepatocytes, cyclin D1 inhibits the 
glucose-mediated induction of lipogenic genes by repressing the carbohydrate response 
element binding protein (ChREBP) and hepatocyte nuclear factor 4α (HNF4α), which are 
important regulators of glucose sensing and lipid metabolism [101]. CDK4 activity is required 
for the inhibition of ChREBP-mediated transcription but unnecessary for HNF4α-regulated 
lipogenesis. Cyclin D1 thus inhibits both glycolysis and lipogenesis, via CDK4-dependent and -
independent mechanisms.  
Moreover, cyclin D1 controls mitochondrial biogenesis and functions by inhibiting the 
nuclear respiratory factor 1 (NRF1). This reduction in mitochondrial activity requires CDK4 
[102]. In B cells, including MM tumor cells, cyclin D1 expression is also linked to a decrease in 
mitochondrial activity. The binding of cyclin D1 to VDAC impairs ADP access to the inner 
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mitochondrial membrane [15]. An analysis of cyclin D1 interactors in various cancer cells 
identified several proteins involved in metabolism, such as fatty acid synthase, a lipogenic 
enzyme, glyceraldehyde-6-phosphodehydrogenase, pyruvate kinase M1/M2, and enolase 1, 
all involved in glycolysis [8, 69 and Caillot et al., in preparation]. Interestingly, Wang and 
coworkers reported that cyclin D3/CDK6 complexes play an unique role in glucose 
metabolism, by phosphorylating and inhibiting two keys enzymes: pyruvate kinase M2 and 6-
phosphofructokinase. This inhibition redirects glycolytic intermediates into the pentose 
phosphate and serine pathways and sustains prosurvival functions [103]. Cyclin D1/CDK4/6 
complexes may have a similar oncogenic function.  
 
Animal models confirm the oncogenic functions of cyclin D1 in vivo 
Gain- and loss-of-function studies in transgenic mice have confirmed the diverse 
functions of cyclin D1, including, in particular, its crucial role in embryogenesis and 
development (not discussed here). The overexpression of cyclin D1 or the expression of the b 
isoform of this protein revealed oncogenic functions. Indeed, in MMTV-cyclin D1 transgenic 
mice in which cyclin D1 is under the control of the mammary tumor virus (MMTV) promoter, 
mammary adenocarcinomas developed in mammary tissues [104]. Cyclin D1 has also been 
shown to be essential for breast cancer maintenance and progression in vivo. Indeed, cyclin 
D1-deficient mice are resistant to MMTV-ErbB2- and MMTV-Ras-induced breast cancers [105]. 
ErbB2-driven mammary carcinomas display arrest and senescence following cyclin D1 knock-
down or the inhibition of CDK4/6 [106]. The kinase activity of CDK4/6 seems to be required 
for breast tumorigenesis, because mice expressing a kinase-deficient mutant form of cyclin D1 
(CCND1 K112E) are protected against ErbB2-induced adenocarcinoma [107]. Cyclin D1 acts as 
a mediator of mammary tumorigenesis induced by ERBB2 in a CDK-dependent manner [108].  
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Transgenic mice expressing CCND1 under the control of thee Eμ enhancer (mimicking 
what occurs in B-cell lymphoma) do not develop detectable lymphoproliferation [109, 110]. 
In sharp contrast, equivalent constructs with the nuclear mutant CCND1 T286A, rather than 
the wild-type gene, induce a mature B-cell lymphoma [59]. Transgenic mice expressing the 
same T286A mutant under the control of the MMTV promoter develop mammary carcinomas 
earlier and at a higher frequency than mice transgenic for MMTV-CCND1 mice [111]. Thus, the 
transformation process may follow two different courses, depending on CCND1 status: if 
CCND1 is overexpressed as a consequence of oncogenic signals, such as RAS, ERBB2 but also 
STATs, Notch, or NF-kB (not documented here), then transformation is dependent on CDK 
activity, whereas, if CCND1 is  overexpressed as a function of mutation or gene rearrangement, 
cyclin D1 is the primary driver for oncogenesis. Hepatocarcinomas, colon carcinomas and skin 
papillomas have been shown to result from the overexpression of cyclin D1, in the appropriate 
transgenic mouse models [27].  
 The notion that the chromosome instability driven by the nuclear cyclin D1 isoform is 
part of the oncogenic process, is also supported by results of in vivo experiments. In the Eμ-
CCND1 T285A transgenic mouse model, malignant lymphocytes display aneuploidy and 
chromosomal translocation due to alterations in DNA replication [84]. Furthermore, an 
enrichment in the expression of genes associated with chromosome instability is observed in 
breast cancer cells in an inducible model of acute cyclin D1 expression in mammary tissue, 
and in the chronic MMTV-CCND1 expression model [10]. In this second transgenic model, the 
kinase-dead mutant (K112E) induces mammary carcinoma, and tumor cells have high 
chromosome instability scores [88]. However, it remains unclear how cyclin D1 regulates the 
chromosome instability-associated genes signature in vivo. It is possible that cyclin D1 
overexpression leads to a conflict between transcription and replication machineries [79]. 
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However, if the downregulation of the global transcriptome, described in B lymphoma cells, 
is a hallmark of cyclin D1-expressing tumors, then an association of transcription inhibitors 
with CDK inhibitors may significantly improve tumor burden.  
 
Open questions 
The two major functions of cyclin D1 associated with tumorigenesis (nuclear functions 
in both cases) are cell cycle regulation and chromosome stability control. Cell cycle control is 
dependent on cyclin D1/CDK4/6 complexes and their kinase activity, whereas chromosome 
stability control is CDK4/6-independent. As for the dysregulation of the cell cycle, the 
induction of chromosome instability is mediated by nuclear cyclin D1. Does the nuclear cyclin 
D1 consist entirely of isoform b or, does it consist of accumulated and mutated isoform a? 
Both isoforms are produced under the control of the same promoter (Figure 1B) and they are 
expressed in concert. However, although cyclin D1b is known to be present in several tumor 
types, it is not clear whether it is systematically produced in these tumors. It is essential to 
resolve this issue, given the oncogenic functions of cyclin D1b. Systematic studies of tumor 
cells with adequate tools for distinguishing between the two isoforms are required.  
The polymorphism (G870A) at the exon 4 splice donor site in CCND1 is responsible for 
the alternative splicing leading to the generation of the b isoform (Figure 1B). The allele with 
a G at nucleotide 870 (codon 242) may preferentially encode the CCND1a transcript whereas 
the allele with an A residue at the same position may encode the b isoform [53]. Nevertheless, 
cyclin D1b is found in tumors homozygous for the G allele in a mouse model of rectal 
carcinogenesis [112]. Moreover, meta-analyses on tumor tissues have yielded inconclusive 
results about the relationship between the A/G polymorphism and tumor initiation and/or 
progression. Two groups have independently characterized RNA binding factors that might 
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control cyclin D1b production [113, 114]. In prostate cancer cells, SRSF1 (serine and arginine-
rich splicing factor 1) preferentially associates with and promotes the accumulation of the 
isoform b transcript from the G allele. SRSF1 is induced during the progression of prostate 
cancer [1131]. In sharp contrast, in the same tumor type, Sam98 directly affects the CCND1 
splicing through a preference for the A allele. Sam98 expression is correlated with cyclin D1b 
accumulation in clinical samples [114]. Interestingly, the catalytic subunit Brm (Brahma) of the 
SWI/SNIF complex involved in chromatin remodeling, described as a regulator of CCND1 
alternative splicing, associates with Sam98 [115]. Several mechanisms impairing cyclin D1b 
production have been identified, but their effects on malignant transformation remain to be 
established. 
 Further insight has been obtained from high-throughput analyses of the cyclin D1 
transcriptome and interactome in tumor cells [8, 63, 69]. More than 100 proteins interacting 
with cyclin D1 have been identified in tumors in different proteomics screens [8, 63, 116]. 
Cyclin D1 interactors are involved in cell cycle regulation, DNA repair, DNA replication, 
metabolic reprogramming, and apoptosis (Table 2). Are these functions physiological or 
associated with gains of function occurring as a consequence of cyclin D1 overexpression? It 
will be important to explore these points in the context of the development of anti-CDK4/6 
therapies.  
 Selective inhibitors of CDK4/6 (CDK4/6i, including palbociclib, the first used in clinic) 
are currently in clinical trials (https://clinicaltrials.gov/) and showed positive outcomes, 
especially for ER-positive breast cancers and B-cell lymphomas [2]. CDK4/6i prevent RB1 
phosphorylation and cause cell cycle arrest in G1. In turn, CDK4/6i show efficacy only if RB1 is 
functional in tumor cells. However, hyperactivation of cyclin E/CDK2 complex which 
substitutes for CDK4/6 and phosphorylate RB1 is one major mechanism of CDK4/6i resistance. 
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This could be due to high levels of CDK2, amplification of CCNE1 (coding for cyclin E), loss of 
p21CIP1 or p27KIP1 [117]. Other than RB1, FOXM1 and SMAD3, both involved in cell 
proliferation, are phosphorylated by cyclin D1/CDK4/6. To our knowledge, the effects of 
CDK4/6i on TGF-β-mediated cell proliferation has not been assessed. Among the CDK4/6 
substrates are cytoskeleton structural proteins and proteins regulating adhesion, migration, 
and invasion (Table 2). Whether CDK4/6i affect these proteins and non-canonical functions of 
cyclin D1 in RB1-negative and RB1-positive tumors remains to be established. In any case, 
CDK4/6i may contribute to a therapeutic effect. It would be of great interest to investigate the 
combination of CDK4/6i with already characterized signaling pathways inhibitors.   
 
Conclusions 
Cyclins D1, D2 and D3 have similar cell cycle regulatory functions. However, only cyclin 
D1 is significantly overexpressed of in solid cancers and hemopathies and has CDK4/6- and 
RB1-independent functions promoting cancer development. Several of these functions - the 
transcription regulation, chromosome stability and migration control - are well-documented 
and known to be involved in tumorigenesis. Others, such as the regulation of metabolism and 
the non-coding genome, are beginning to emerge, opening up to new perspectives for cancer 
management, but also rendering our vision more complex.  
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Figure legends 
 
Figure 1. Structure and function of cyclins and cyclin D1  
A. Schematic representation of the cell cycle. Following mitogenic signals, eukaryotic cells exit 
quiescence and irreversibly enter in G1 phase after the restriction (R) point. The successive 
G1, S, G2 and M phases are controlled by cyclins and their cognate CDKs, as indicated. B. 
Structure of the CCND1 gene, mRNAs and cyclin D1 proteins. The CCND1 gene (NG-007375.1) 
comprises five exons (E1-5) separated by four introns (I1-4). It encodes the full-length 
canonical cyclin D1 product (cyclin D1a) of 295 amino acids (aa). Through alternative splicing, 
CCND1 generates two types of mRNA: the canonical form (NM_053056.2) and the so-called 
“b” form, which includes the intron 4 encoding an additional stretch of 33 amino acids. The 
corresponding protein isoforms, “a” and “b”, are identical over the first 240 amino acids from 
the N-terminus, but have different C-termini. Isoform “b” lacks the threonine 285 residue and 
the PEST sequence (aa 241-290) required for degradation, and the LxxLL motif (aa 251-257) 
required for ligand-dependent interactions with nuclear receptors. By contrast, both isoforms 
contain the cyclin box required for CDK4/6 and CIP1/KIP1 family binding, and the LxCxE motif 
(aa 5-9) required for RB1 binding. C. Schematic representation of the G1-to-S phase transition. 
For cells to exit quiescence (G0), they require mitogenic signals that activate the RAS signaling 
pathways and, to a lesser extent, the Wnt/β-catenin and NF-κB pathways. Cyclin D1 is 
activated at several levels after its translation: stability, assembly with its CDK4/6 partners, 
and import into the nucleus via the CKIs of the CIP/KIP family. Cyclin D1/CDK4/6 complexes 
accumulate during the G1 phase, until the start of DNA replication. Cyclin D1 is then exported 
to the cytoplasm, where it is degraded by UPS. Cyclin D1/CDK4/6 phosphorylates and 
inactivates RB1 (and pocket proteins RBL1/2, p107 and p130) facilitating the dissociation of 
E2F transcription factors and the activation of the necessary genes for DNA synthesis. Cyclin 
D1 degradation is required for the progression of S phase. The GSK3β kinase phosphorylates 
cyclin D1, which is then taken up by XPO1 and exits the nucleus. Specific E3 ubiquitin ligases 
ubiquitinylate cyclin D1, which is then degraded by the proteasome machinery [65].  
 
Figure 2. Deregulation of CCND1 in human cancers  
A. The frequencies of mutation, amplification, and deletion in human cancers are depicted in 
the graph. Data were obtained from the cBioPortal for Cancer Genomics 
(//www.cbioportal.org/). We analyzed 10,259 samples from 9,682 patients with 25 different 
cancers from the Cancer Genome Atlas. B. The types and frequencies of missense, in-frame 
and truncating mutations of CCND1 observed with regards to the cyclin D1 protein structure 
are shown.  
 
Figure 3. Nuclear functions of cyclin D1 
Cyclin D1 activity associated with CDK4/6 is the canonical function of this protein in the control 
of the cell cycle and cell proliferation. Once activated, cyclin D1/CDK4/6 complexes 
phosphorylate RB1 (and RBL1/2), leading to their inactivation and the release of E2F family 
members. The transcriptional program controlled by E2F includes a battery of genes required 
for G1-to-S phase transition [45]. In addition to its role in cell cycle regulation independent of 
kinase activity, cyclin D1 acts in complexes with CDK4/6, to sequester the CKIs p21CIP1 and 
p27KIP1, thereby indirectly controlling the activity of cyclin E/CDK2 complexes acting during 
the transition G1-to-S. Cyclin D1/CDK4/6 complexes phosphorylate SMAD3 and downregulate 
the transcription of genes involved in growth inhibition from TGF-β family [67].  
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Cyclin D1/CDK4 complexes phosphorylate the MEP50 cofactor for PRMT5, an arginine 
methyltransferase controlling methylation and transcriptional repression. In a mouse model 
of B-cell lymphomagenesis, Aggarwal and coworkers showed that nuclear cyclin D1 triggered 
an increase in MEP50/PRMT5 activity, decreasing the activity of CUL4, the E3 ligase of CDT1, 
the replication licensing protein. Moreover, PRMT5 appears to be necessary for cyclin D1-
mediated transformation [118]. However, unlike the targeting of RB1, SMAD3 and FOXM1, 
this seems to be important during the S phase. We did not comment on this point in the text, 
but we recommend another recent review including this aspect [77]. Forkhead box M1 
(FOXM1) is a critical target of cyclin D1/CDK4/6. Once stabilized by phosphorylation, FOXM1 
maintains G1/S phase expression, and protects cancer cells from senescence [68]. FOXM1 
appears to be an oncogenic driver for solid tumors [119]. 
Independently of CDK4/6, cyclin D1 upregulates (ERα) or downregulates (AR, PPARs) nuclear 
receptor-mediated transcription by binding directly to the receptors and their co-activators 
(SRC1, AIB1). This regulation may occur directly or through the recruitment of chromatin 
modifiers of the histone deacetylase or acetyltransferase families (HDAC, HAT) and SuV39H, 
HP1α.  
Finally, cyclin D1 binds to proteins of the DNA repair machinery (BRCA1/2, RAD51) and 
participates to both NHEJ and HR mechanisms of DNA repair. 
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Table 1. Cytoplasmic functions of cyclin D1 in adhesion, migration and invasion 
 
Cell type CDK4/6 activity Target Cytoplasmic form Function Reference 
Fibroblast Yes ROCK2/Cofilin 
TSP1 
not reported Adhesion 
Migration 
[120] 
Mammary epithelial  
cell* 
No 
 
p27KIP1 
 
Yes Migration [17] 
Mammary epithelial  
cell 
Yes RHOA/ROCK2 not reported Migration [18] 
Breast  cancer Yes Filamin A not reported Migration 
Invasion 
[24] 
Prostate** 
Fibroblast 
not reported PACSIN 2 YES Migration [121] 
Prostate cancer 
Fibroblast 
Yes Paxillin/RAC1 not reported Membrane  ruffling 
Invasion 
[62] 
Multiple myeloma not reported F-actin fiber 
ERK1/2 signaling 
not reported Adhesion [122] 
Mantle cell lymphoma not reported Cytoskeleton 
proteins 
Yes Migration 
Invasiveness 
[63] 
Glioblastoma Yes Paxillin/RAC1 
RALA 
Yes Tumor dissemination [64] 
* In this report, it was shown that the nuclear cyclin D1b form failed to bind p27KIP1, to inhibit RHOA/ROCK activity and had no effect on cell 
migration. ** In this report, cyclin D1b failed to bind PACSIN B and to repress cell migration. Abbreviations: ERK1/2, extracellular signal-regulated 
kinase 1/2 or MAPK1/2; KIP1, kinase inhibitory protein or CDKN1B, cyclin-dependent kinase inhibitor 1B; RAC1, RAC family small GTPase 1; ROCK, 
RHO-associated coiled coiled containing protein kinase; TSP1, thrombospondin 1. 
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Table 2. Pathway enrichment analysis of cyclin D1 partners in human cancer cell lines 
 
Name WikiPathway Adj. 
p-value 
Odds ratio Score 
DNA damage response WP707 1.88e-12 24.99 828.50 
miRNA regulation of DNA damage   
response 
WP1530 1.14e-12 23.93 779.21 
Retinoblastoma gene in cancer WP2446 1.01e-12 21.04 695.86 
G1-to-S cell cycle control WP45 1.81e-10 22.47 606.18 
DNA mismatch repair WP531 7.65e-4 43.57 446.26 
Cell cycle WP179 5.06e-11 15.25 434.30 
miRNAs involved in DNA damage 
response 
WP1545 1.24e-4 34.86 431.49 
Integrated cancer pathway WP19718 1.24e-4 20.80 354.06 
Signaling pathway in glioblastoma WP2261 5.36e-8 15.94 336.47 
Valproic acid pathway WP3871 2.15e-3 30.17 272.67 
DNA replication WP466 3.26e-5 18.67 263.14 
DSBs and cellular response via 
ATM 
WP3959 9.40e-6 16.64 256.68 
Rb-E2F1 signaling WP3969 2.62e-3 28.01 246.60 
FSGS WP2572 4.55e-6 14.52 237.87 
DSBs and cellular response via ATR WP4016 9.31e-6 13.07 203.19 
PPARα pathway WP2878 8.49e-4 20.11 202.12 
Apoptosis-related network 
(Notch) 
WP2864 1.12e-4 14.80 187.71 
ATM signaling pathway WP2516 3.41e-4 16.34 183.82 
Metabolic reprogramming WP4290 4.13e-4 15.56 171.26 
IL-1 induced NF-κB activation WP3656 2.70e-2 26.14 156.50 
The 153 proteins identified as cyclin D1 interactors in at least one of the five cancer cell line 
tested by Sicinski’s group (mantle cell lymphoma, breast cancers, pharyngeal cancer, colon 
cancer, [8]) were analyzed with the Enrichr tool [123] for enriched WikiPathways [124] The 
top 20 enriched pathways are indicated. 
Abbreviations: Adj., adjusted; ATM, ataxia telangiectasia mutated; ATR; ataxia telangectasia 
and Rad3 related; DSB, double-strand break; FSGS, primary focal glomerulosclerosis; IL, 
interleukin; NF-κB, nuclear factor κB; PPAR, peroxisome proliferator-activated  
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